Revolutionary AMD Treatment: MacuMira Unveils Health Canada-Approved Device for Eye Care Professionals

Canadian company MacuMira Medical Devices has launched a groundbreaking treatment for dry age-related macular degeneration (AMD), recently approved by Health Canada. This innovative technology, called the MacuMira system, is now available in over 150 clinics nationwide. It uses low-dose microcurrent stimulation applied through closed eyelids during 32-minute sessions.

Justin Sather, CEO of MacuMira, highlighted the system’s potential impact: “For those affected by dry AMD, everyday tasks like reading or recognizing loved ones can be challenging. This treatment could make a real difference.”

The MacuMira system works by stimulating retinal cells, improving mitochondrial function, and reducing inflammation. In Canada alone, more than 15,000 treatments have been performed. A randomized controlled trial published in the International Journal of Retina and Vitreous showed significant enhancements in patients’ visual acuity and contrast sensitivity.

Dr. Amit Gupta, an ophthalmologist and retina specialist at Clarity Eye Institute in Toronto, expressed optimism about this technology, noting, “It’s encouraging to see new options for patients who previously had little hope for treatment.”

This approval follows a wave of recent advancements in eye care in Canada. For example, in July, Health Canada approved Alcon’s Clareon Panoptix Pro intraocular lens (IOL) for cataract patients. This IOL boasts a unique technology that aims to deliver superior light performance.

Additionally, July saw the approval of Eylea’s Aflivu (aflibercept) for various retinal diseases. It marked Canada’s first ophthalmic biosimilar. In August, Sandoz Group AG partnered with Lupin to market a biosimilar ranibizumab, while Roche Canada announced that Vabysmo will now be funded in Quebec for treating macular edema due to retinal vein occlusion.

Recent statistics reveal a growing demand for effective retinal treatments. The global market for retinal disease treatments is projected to reach $46.5 billion by 2028, indicating a strong focus on developing innovative solutions for vision impairments.

With these recent approvals and advancements, patients have more hope than ever for managing AMD and maintaining their quality of life. For more details on MacuMira’s device, you can visit their official announcement here.

Source link